Screening of chronic active hepatitis from series of health examination database

Journal of Internal Medicine of Taiwan

Volumn 15, Issue 2, 2004, Pages 65-75

  Tung, Wei Chih ^b   Lu, Sheng Nan ^b   Wu, Mei Huei ^a   Chen, Chien Jen ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Anti HCV; Chronic active hepatitis; HBsAg; Hepatocellular carcinoma; Liver cirrhosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY DETECTION; ANTIGEN DETECTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; CLINICAL EXAMINATION; COMMUNITY CARE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DATA BASE; DISEASE ACTIVITY; FEASIBILITY STUDY; HIGH RISK POPULATION; HUMAN; INFECTION CONTROL; LIVER DISEASE; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; PATIENT REFERRAL; PILOT STUDY; PREDICTION; PREVALENCE; SCREENING; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; VOLUNTEER;

EID: 2942635233     PISSN: 10167390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. National Health Administration, Republic of China. Health Statistics 2. Vital Statistics, 2002, Nation Health Administration, Taipei, 2003.
2. Chu CM. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 2000; 15 Suppl: E25-30.
3. Lu SN, Lee CM, Changchien CS, Chen CJ. Excess mortality from hepatocellular carcinoma in an HCV-endemic township of an HBV-endemic country (Taiwan). Trans R Soc Trop Med Hyg 1999; 93: 600-2.
4. Sun CA, Wu DM, Lin CC, et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 2003; 157: 674-82.
5. Wu JC, Lee SD, Hsiao KJ, et al. Mass screening of primary hepatocellular carcinoma by alpha-fetoprotein in a rural area of Taiwan-a dried blood spot method. Liver 1988; 8: 100-4.
6. Yu MW, Hsu FC, Sheen IS, et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997; 145: 1039-47.
7. Liaw YF, Tai DI, Chu CM, et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 1986; 90: 263-7.
8. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-74.
9. Yuen MF, Lai CL. Natural history of chronic hepatitis B virus infection. J Gastroenterol Hepatol 2000; 15: E20-4.
10. Amarapurkar D. Natural history of hepatitis C virus infection. J Gastroenterol Hepatol 2000; 15: 105-10.
11. Tabor E. Interferon for preventing and treating hepatocellular carcinoma associated with the hepatitis B and C viruses. Dig Liver Dis 2003; 35: 297-305.
12. Chen CJ, Lu SN, You SL, et al. Community-based hepatocellular carcinoma screening in seven townships in Taiwan. J Formos Med Assoc 1995; 94: S94-102.
13. Chen TH, Chen CJ, Yen MF, et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer 2002; 98: 257-61.
14. Liu TY, Lu SN, Su WP, et al. Prediction of fatty liver from serum triglyceride levels and body weight indexes. Gaoxiong Yi Xue Ke Xue Za Zhi 1990; 6: 289-94.
15. Vertuani S, Bazzaro M, Gualandi G, et al. Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals. Eur J Immunol 2002; 32: 144-54.
16. Lin CC, Hwang SJ, Chiou ST, et al. The prevalence and risk factors analysis of serum antibody to hepatitis C virus in the elders in northeast Taiwan. J Chin Med Assoc 2003; 66: 103-8.
17. Kyrlagkitsis I, Portmann B, Smith H, O'Grady J, Cramp ME. Liver histology and progression of fibrosis in individuals with chronic hepatitis C and persistently normal ALT. Am J Gastroenterol 2003; 98: 1588-93.
18. Huang WS, Lu SN, Wang JH, et al. Prediction of viremia for case of hepatitis C virus (HCV) infection using a third-generation anti-HCV enzyme immunoassay test. Hepatogastroenterology 2004 (in press).
19. Chang WY, Chen CJ, Lu SN, et al. Relationship between fatty liver, alanine aminotransferase, HBsAg and hepatitis C virus. J Gastroenterol Hepatol 1992; 7: 455-8.
20. Lin DY, Sheen IS, Chiu CT, et al. Clinical significance of ultrasonographic fatty liver in asymptomatics: analysis of 1040 check-up subjects. J Med Ultrasound 1994; 1: 165-171.
21. Huang JF, Lu SN, Chue PY, et al. Hepatitis C virus infection among teenagers in an endemic township in Taiwan: epidemiological and clinical follow-up studies. Epidemiol Infect 2001; 127: 485-92.
22. Yu ML, Chuang WL, Chen SC, et al. Changing prevalence of hepatitis C virus genotypes: molecular epidemiology and clinical implications in the hepatitis C virus hyperendemic areas and a tertiary referral center in Taiwan. J Med Virol 2001; 65: 58-65.
23. Lu SN, Wang JH, Kuo YK, et al. Predicting the prevalence of antibody to hepatitis C virus (HCV) in a community by the prevalence of elevated levels of alanine aminotransferase: a method to identify areas endemic for HCV. Am J Trop Med Hyg 2002; 67: 145-50.
24. Wang LY, Hatch M, Chen CJ, et al. Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int J Cancer 1996; 67: 620-5.
25. Sun CA, Wu DM, Wang LY, Chen CJ, You SL, Santella RM. Determinants of formation of aflatoxin-albumin adducts: a seven-township study in Taiwan. Br J Cancer 2002; 87: 966-70.
26. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971-5.
27. Leung N. Treatment of chronic hepatitis B: case selection and duration of therapy. J Gastroenterol Hepatol 2002; 17: 409-14.
28. Buti M, Morral S, Sanchez F, Martell M, Stalgis C, Esteban R. High-Dose interferon-alpha 2b plus ribavirin for retreatment of interferon-nonresponsive patients infected with genotype 1 hepatitis C virus. Dig Dis Sci 2001; 46: 2396-400.
29. Arif A, Levine RA, Sanderson SO, et al. Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin. Dig Dis Sci 2003; 48: 1425-30.
30. Omata M, Yoshida H. Resolution of liver cirrhosis and prevention of hepatocellular carcinoma by interferon therapy against chronic hepatitis C. Scand J Gastroenterol 2003; 237: 47-51.